We have been covering the 5 keys to investment this year. The first three:
1. US business cycle appears to be aging in reverse.
2. Industrial Renaissance is fueling a new era of growth
3. AI megatrend could boost stocks for years
4. Drug discovery is creating a golden age of health care
Following last year’s U.S. election, uncertainty over the industry’s regulatory outlook sparked a slump in health care stocks, further pressuring a sector that had lagged throughout the year. But following the sell-off, many companies are trading at attractive valuations, creating opportunities for investors with a long-term approach.
“That includes forgotten pharma, or drugmakers that don’t offer weight loss treatments,” according to Cheryl Frank, portfolio manager for American Mutual Fund® and CGCV — Capital Group Conservative Equity ETF. “I am looking for opportunities to invest in dividend payers that have been left behind by the market.”
While weight loss drugs, such as GLP-1s, tend to capture the spotlight, advances are being made on many other fronts. The largest pharmaceutical companies have more than two hundred drugs in their pipelines.
As these companies tackle some of the world’s most debilitating ailments, patients have experienced lower mortality rates and longer life expectancies. Over the next decade, we could see effective treatments for ALS, sickle cell and muscular dystrophy. Risks are always present when investing in biotech and pharma companies, but we could be at the start of a golden age of health care — for patients and investors.
"This material is provided for general information and is subject to change without notice. Every effort has been made to compile this material from reliable sources however no warranty can be made as to its accuracy or completeness. The information does not represent, warrant or imply that services, strategies or methods of analysis offered can or will predict future results, identify market tops or bottoms or insulate investors from losses. Past performance is not a guarantee of future results. Investors should always consult their financial advisor before acting on any information contained in this newsletter. The information provided is for illustrative purposes only. The opinions expressed are those of the author(s) and not necessarily those of Geneos Wealth Management, Inc.